Clinical Trial Update: Open Label Trial to Assess Iressa in Prostate Cancer Patients [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating the EGFR inhibitor Iressa (gefitinib) in patients with prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED